Dual function of interleukin-23 Aptamer to suppress brain inflammation via attachment to macrophage stimulating 1 kinase and interleukin-23

Sardou, Hossein Shahdadi; Jebali, Ali; Iman, Maryam

doi:10.1016/j.colsurfb.2019.110619

Cited by 14 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IL-23 aptamer treatment resulted in a significant reduction in the number of inflammatory infiltration foci, as evidenced by histological and immunohistochemical analyses. Furthermore, the IL-23 aptamer was found to reduce the absolute and relative numbers of MST1+CD4+ Th1 cells, as well as IL-23-producing cells, indicating a reduced neuroinflammatory response and protection of the brain from damage [215].…”

Section: Aptamers Targeting Proinflammatory Cytokines and Chemokinesmentioning

confidence: 97%

“…Aptamers can act as antagonists that bind to specific receptors and block the biological response of the receptor to its pro-or anti-inflammatory mediators, thereby suppressing or counteracting their effects [209]. Most aptamers have been developed to specifically target a range of inflammatory mediators, including interleukins (IL-2, IL-6, IL-10, IL-11, IL-17, IL-23, IL-32), transforming growth factor-β (TGF-β) [210], tumour necrosis factor-α (TNF-α) [211], proinflammatory cytokines, interferon-γ (IFN-γ), chemokines (CCL2, IP-10), and their related receptors, as well as certain inflammatory autoantigens [212][213][214][215].…”

Section: Therapeutic Aptamers Targeting Neuroinflammationmentioning

confidence: 99%

See 1 more Smart Citation

Exploring the Potential of Aptamers in Targeting Neuroinflammation and Neurodegenerative Disorders: Opportunities and Challenges

Kong

et al. 2023

IJMS

View full text Add to dashboard Cite

Neuroinflammation is the precursor for several neurodegenerative diseases (NDDs), such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and multiple sclerosis (MS). Targeting neuroinflammation has emerged as a promising strategy to address a wide range of CNS pathologies. These NDDs still present significant challenges in terms of limited and ineffective diagnosis and treatment options, driving the need to explore innovative and novel therapeutic alternatives. Aptamers are single-stranded nucleic acids that offer the potential for addressing these challenges through diagnostic and therapeutic applications. In this review, we summarize diagnostic and therapeutic aptamers for inflammatory biomolecules, as well as the inflammatory cells in NDDs. We also discussed the potential of short nucleotides for Aptamer-Based Targeted Brain Delivery through their unique features and modifications, as well as their ability to penetrate the blood-brain barrier. Moreover, the unprecedented opportunities and substantial challenges of using aptamers as therapeutic agents, such as drug efficacy, safety considerations, and pharmacokinetics, are also discussed. Taken together, this review assesses the potential of aptamers as a pioneering approach for target delivery to the CNS and the treatment of neuroinflammation and NDDs.

show abstract

Section: Aptamers Targeting Proinflammatory Cytokines and Chemokinesmentioning

confidence: 97%

Section: Therapeutic Aptamers Targeting Neuroinflammationmentioning

confidence: 99%

Exploring the Potential of Aptamers in Targeting Neuroinflammation and Neurodegenerative Disorders: Opportunities and Challenges

Kong

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…It is reported that DNA aptamer RA10-6, which binds to IL-17A receptor, can inhibit IL-17A binding and reduce synovial inflammation in mice with osteoarthritis ( Chen et al, 2011 ). Meanwhile, studies have shown that DNA aptamer IL-23 can detect and control brain inflammation ( Shahdadi Sardou et al, 2020 ). Ceria nanoparticle gelatin hydrogel coated with aptamers targeting IL-17 can significantly reduce the level of inflammation in brain tissue by reducing the expression and serum concentration of IL-17, IL-10 and IL-6 ( Hekmatimoghaddam et al, 2019 ).…”

Section: Therapeutic Applications Of Inhibitory Odns In Immune-mediat...mentioning

confidence: 99%

Advances in the mechanisms and applications of inhibitory oligodeoxynucleotides against immune-mediated inflammatory diseases

Wang

Chen

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Inhibitory oligodeoxynucleotides (ODNs) are short single-stranded DNA, which capable of folding into complex structures, enabling them to bind to a large variety of targets. With appropriate modifications, the inhibitory oligodeoxynucleotides exhibited many features of long half-life time, simple production, low toxicity and immunogenicity. In recent years, inhibitory oligodeoxynucleotides have received considerable attention for their potential therapeutic applications in immune-mediated inflammatory diseases (IMIDs). Inhibitory oligodeoxynucleotides could be divided into three categories according to its mechanisms and targets, including antisense ODNs (AS-ODNs), DNA aptamers and immunosuppressive ODNs (iSup ODNs). As a synthetic tool with immunomodulatory activity, it can target RNAs or proteins in a specific way, resulting in the reduction, increase or recovery of protein expression, and then regulate the state of immune activation. More importantly, inhibitory oligodeoxynucleotides have been used to treat immune-mediated inflammatory diseases, including inflammatory disorders and autoimmune diseases. Several inhibitory oligodeoxynucleotide drugs have been developed and approved on the market already. These drugs vary in their chemical structures, action mechanisms and cellular targets, but all of them could be capable of inhibiting excessive inflammatory responses. This review summarized their chemical modifications, action mechanisms and applications of the three kinds of inhibitory oligodeoxynucleotidesin the precise treatment of immune-mediated inflammatory diseases.

show abstract

“…IL-22 is a powerful pro-inflammatory cytokine. Inflammatory cytokines including COX-2, PGE2, IL-6, and TNF-α have a role in various degenerative brain illnesses, according to pathological research ( Ennerfelt and Lukens, 2020 ; Shahdadi Sardou et al, 2020 ; Daily et al, 2021 ). The expression levels of inflammatory cytokines were upregulated in IL-22-treated neuronal cells and glial cells.…”

Section: Il-22 In Neurodegenerative Diseasementioning

confidence: 99%

Interleukin 22 and its association with neurodegenerative disease activity

et al. 2022

View full text Add to dashboard Cite

It is worth noting that neuroinflammation is well recognized as a symptom of neurodegenerative diseases (NDs). The regulation of neuroinflammation becomes an attractive focus for innovative ND treatment technologies. There is evidence that IL-22 is associated with the development and progression of a wide assortment of NDs. For example, IL-22 can activate glial cells, causing them to generate pro-inflammatory cytokines and encourage lymphocyte infiltration in the brain. IL-22 mRNA is highly expressed in Alzheimer’s disease (AD) patients, and a high expression of IL-22 has also been detected in the brains of patients with other NDs. We examine the role of IL-22 in the development and treatment of NDs in this review, and we believe that IL-22 has therapeutic potential in these diseases.

show abstract

Dual function of interleukin-23 Aptamer to suppress brain inflammation via attachment to macrophage stimulating 1 kinase and interleukin-23

Cited by 14 publications

References 27 publications

Exploring the Potential of Aptamers in Targeting Neuroinflammation and Neurodegenerative Disorders: Opportunities and Challenges

Exploring the Potential of Aptamers in Targeting Neuroinflammation and Neurodegenerative Disorders: Opportunities and Challenges

Advances in the mechanisms and applications of inhibitory oligodeoxynucleotides against immune-mediated inflammatory diseases

Interleukin 22 and its association with neurodegenerative disease activity

Contact Info

Product

Resources

About